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ABSTRACT 
Previous studies have shown that L-tryptophan treatment has been known to 
reduce blood pressure (BP) in hypertensive rats. L-tryptophan is converted to serotonin 
(5-HT), a potent vasoconstrictor agonist. The direct vascular effects of L-tryptophan, an 
essential amino acid, and the mechanism that contributes to the fall in BP have not been 
fully explored. The present study aims to examine the direct vascular responses to both 
D- and L- tryptophan using perfused mesenteric vascular bed, an ex-vivo preparation that 
represents the resistance function of circulation.  Perfusion was maintained at a constant 
flow rate (5 mL/min) with Krebs buffer (pH 7.4, 37˚C) after isolation from 12 to 14 week 
old male Sprague-Dawley rats.  The basal perfusion pressure (PP) (mean ± SEM) was 27 
± 3 mmHg. Inclusion of D- and L-isomers in the perfusion medium led to concentration-
dependent increase in PP. While the maximal response (Emax) was similar, D-tryptophan 
(EC50: 0.25 ± 0.12* µmol; Emax: 128 ± 8 mmHg) was more potent (lower EC50 value; *p 
< 0.01) than L-tryptophan (EC50: 0.79 ± 0.30 µmol; Emax: 141 ± 7 mmHg).  Inclusion of 
increasing concentrations (2, 5 and 10 nM) of the 5-HT2A selective antagonist, ketanserin, 
led to parallel right-ward shifts in the concentration-response curves to D- and L-
tryptophan with restoration of their Emax.  In contrast, the α1 selective agonist, 
methoxamine (30 µM), constricted preparations, both D- (IC50: 0.94 ± 0.30* µmol; Imax: 
96 ± 2%) and L-tryptophan (IC50: 2.8 ± 1.0 µmol Imax: 88± 1%) evoked concentration-
dependent vasodilatation, an effect that was resistant to blockade by either ketanserin or 
other 5-HT antagonists.  Again, D-tryptophan was more potent than L-tryptophan in the 
presence of 5-HT antagonist (*p < 0.05). Neither the removal of endothelium nor 
incubation with selective inhibitors of dilatory mediators released from the endothelium, 
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failed to alter the vasodilator responses to D- and L-tryptophan. In potassium chloride 
depolarized preparations, L-tryptophan evoked an additive vasoconstrictor response.  The 
vasodilator responses to L-tryptophan persisted in the presence of glibenclamide, a KATP 
channel inhibitor, or tetraethyl ammonium, a BKCa channel inhibitor, or BaCl2, a Kir 
channel inhibitor, or ouabain, a Na+-K+-ATPase pump inhibitor.  These data confirm that 
the essential amino acid, L-tryptophan, as well as its D-isomer, evoke a biphasic 
vasoconstrictor and vasodilator responses in the resistance type mesenteric vascular bed.  
While the vasoconstrictor responses are mediated by activation of vascular 5-HT 
receptors, the endothelium-independent vasodilator responses are not linked to activation 
of vascular 5-HT receptors, vascular potassium channels, Na+-K+-ATPase pump or via 
inhibition of voltage-operated Ca2+-channels.  Plasma concentration of L-tryptophan is 
about 90 - 120 µM.  The endothelium/5-HT independent direct vasodilator responses 
characterized here for the first time could account for the antihypertensive/ BP lowering 
effect of L-tryptophan reported earlier by other laboratories. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Introduction to blood vessels 
The blood vessels are one of the major components of the circulatory system that 
transport blood throughout the body. Blood vessels mainly include: a) arteries, which 
carry oxygenated blood from the heart to various tissues (with the exception of 
pulmonary artery which carries deoxygenated blood); b) capillaries, which facilitate the 
exchange of oxygen, carbon dioxide, water and other chemicals between the blood and 
various tissues of the body and c) veins, which carry impure blood from the capillaries 
and returns back to the heart (with the exception of pulmonary vein which carries pure 
blood). However, arteries and veins can be further classified into aorta, arterioles, venules 
and venacava. This cycle of blood circulation from heart to peripheral organs and back to 
heart is maintained throughout one’s life.  
 
Anatomically, arteries and veins are composed of 3 layers namely tunica intima 
(innermost layer), tunica media (middle layer) and tunica adventitia (outermost layer). 
Major arteries like aorta and arterioles are also endowed with a thin inner lining of 
endothelial cells (EC). Occasionally, connective tissue is also found. The tunica 
adventitia layer is formed of connective tissue.  It contains nerves that innervate the 
muscular layer, as well as nutrient capillaries in the larger blood vessels. Tunica media is 
composed of vascular smooth muscle cells (VSMC) along with few fibroblast cells. The 
contractile effect of VSMC contributes to the overall maintenance of the tone of the 
blood vessel. Major function of this layer is to maintain the tone of the blood vessel. The 
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innermost layer known as the tunica intima is directly in contact with the blood. It is 
composed of thin layer of EC sitting on the basement membrane which distinguishes 
intima from the media. EC of tunica intima perform critical functions in homeostasis, 
leukocyte trafficking into the vessel wall and in regulating vascular tone (Esper et al., 
2006). Recent studies show that endothelial dysfunction has been allied with various 
pathological conditions such as atherosclerosis, diabetes, hypertension, 
hypercholesterolemia and inflammation (Grover-Pa´ez et al., 2009). Some of the major 
beneficial regulatory effects exerted in physiological states (with normal endothelium) 
and the deleterious effects encountered following dysfunctional endothelium is given in 
the Figure 1 below. 
 
Vasodilatation        
Thrombolysis 
Platelet disaggregation 
Antiproliferation 
Antiinflammation 
Antioxidant 
 
 
 
 
Figure 1: Regulatory functions of the endothelium. A comparison of the characteristics 
of normal vs dysfunctional endothelium (Figure modified from Esper et. al., 2004). 
 
 
 
Dysfunctional Endothelium Normal Endothelium 
Vasoconstriction 
Thrombosis 
Platelet aggregation 
Leukocyte adhesion 
Inflammation 
Oxidant activity 
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1.2 Endothelium and regulation of vascular tone 
Analogous to other muscle cells, VSMC also contract when intracellular free calcium 
[Ca2+]i level is increased. The relation between increase in [Ca2+]i and contraction is much 
less in VSMC as compared to the striated or cardiac muscle. Vasoconstrictors and 
vasodilators operate by increasing or decreasing [Ca2+]i, and/or by varying the contractile 
sensitivity of the VSMC to elevated [Ca2+]i. Few examples of endogenous  
vasoconstrictors are norepinephrine, angiotensin II, vasopressin, endothelin-1 (ET-1) etc. 
Few examples of endogenous vasodilators are nitric oxide (NO), atrial natriuretic peptide 
(ANP), prostacyclin (PGI2), calcitonin gene related peptide (CGRP) etc. 
 
A new chapter in the regulation of vascular tone was opened with the discovery that 
endothelial layer not only acts as a physical barrier between plasma and extracellular 
fluid but it is an important source of numerous potent mediators (Furchgott et. al., 1989). 
Activation of endothelial receptors or mechanical forces exerted on EC releases factors 
that contract [thromboxane (TXA2) and ET-1] or relax vascular smooth muscle (VSM) 
(Boulanger et al., 1994).  
 
1.2.1 Contractile factors 
Endothelin: In 1985, Hickey et al. showed that a vasoconstrictor factor was produced by 
cultured EC. This was later identified as endothelin, a 21-residue peptide, by Yanagisawa 
et al. in 1988, who isolated, analyzed and cloned the gene for this peptide. Three genes 
encode different sequences (ET-1, ET-2 and ET-3). Later, it was found that these 
isoforms are expressed in various tissues. Two receptors for ET-1 are known at present as 
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the ETA and the ETB receptor (Pollock et al., 1998). ETA receptor has high affinity for 
both ET-1 and ET-2 but low affinity for ET-3, while ETB receptor has equal affinity for 
all 3 isoforms of ET (Arai et. al., 1990; Sakurai et. al., 1990). Both ETA and ETB are 
expressed on VSMC but ETA appears to be more predominant and is responsible for 
vasoconstriction. ETB receptors are mainly found on endothelium and are also known as 
“clearance receptors” since it clears 80% of circulating endothelin from plasma and 
causes vasodilatation (Luscher and Barton, 2000; Kedzierski and Yanagisawa, 2001). 
The signal transduction of endothelin is shown in the Figure 3 on the next page. 
 
Figure 2: Signal transduction of endothelin. ET-1 synthesis is controlled via regulation 
of gene transcription and/or ECE activity and its release occurs mostly abluminally. ET-1 
acts on ETA and ETB smooth muscle receptors to induce vasoconstrictor, pro-oxidant, 
pro-inflammatory and mitogenic responses. ET-1 also acts in an autocrine manner, at 
endothelial cell ETB receptors, to stimulate the release of vasorelaxant agents such as NO 
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and PGI2 (prostaglandin I2). ETB receptors present on kidney and lung endothelial cells 
also remove ET-1 from the circulation, functioning as clearance receptors. AA, 
arachidonic acid; eNOS, endothelial NOS. (Fig 3 is taken with permission from Tostes et. 
al., 2008 – See Appendix at the end). 
  
Thromboxane (TXA2): TXA2 is produced during the catalysis of arachidonic acid by 
cyclooxygenase (COX) followed by thromboxane synthase (TXS). It is a prostaglandin 
(PGH2) derivative. After the development of specific agonists and antagonists of TXA2 in 
1980s, human TXA2 receptor protein was first purified by Narumiya's group (Ushikubi et 
al., 1989). On the other hand, platelets are well known to produce TXA2 in response to 
various stimuli, via the actions of COX and TXS (Hamberg et al., 1975). In addition to 
platelets, many cells/tissues have been shown to produce TXA2 via COX and TXS (Shen 
and Tai, 1986). Signal transduction of TXA2 via G-protein coupling is shown in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
       TXA2 
TP 
Gαq/11 
PLC-β 
IP3/DAG 
Ca2+/PKC 
Physiological 
Response 
Gα12/13 
P115-RhoGEF 
Rho 
Rho signal 
Gβγ 
Gβγ signal 
PI3K, MAPK, 
PLC-β etc. 
Gαi Gαs 
AC 
cAMP  
signal 
Gh 
PLC-δ 
IP3/DAG 
Ca2+/PKC  
signal 
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Figure 3: G-protein coupling of TXA2 and signal transduction. AC, adenylyl cyclase; 
cAMP, cyclic adenosine monophosphate; DAG, diacylglycerol; IP3, inositol 1,4,5-
trisphosphate; p115-RhoGEF, p115 guanine nucleotide exchange factor for Rho; PI3K, 
phosphatidylinositol 3- kinase; PLC-β, phospholipase C-β; PLC-δ, phospholipase C-δ;; 
MAPK, mitogen-activated kinase; PKC, protein kinase C (Diagram reproduced and 
modified from Nakahata N, 2008). 
 
1.2.2 Relaxing factors  
Some factors released from the endothelium lead to vascular smooth muscle 
relaxation. These factors include prostacyclin (PGI2), Nitric oxide (NO) and as yet 
uncharacterized endothelium-derived hyperpolarizing factor (EDHF). 
 
Nitric Oxide (NO): Factors which are both, produced and released by endothelium are 
known as endothelium-derived relaxing factor (EDRF). This factor released by 
endothelium which resulted in vascular smooth muscle relaxation was later found to be 
nitric oxide. EDRF was discovered and characterized by Robert F. Furchgott, a winner of 
the Nobel Prize in Medicine in 1998 along with his co-researchers Louis J. 
Ignarro and Ferid Murad. Signal transduction of NO is shown in Figure 4. 
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Figure 4: Molecular basis for endothelium-dependent vasorelaxation. NO, H2S, and PGI2 
are produced from the endothelium by NOS, CSE, and COX-1, respectively. They are 
released from the endothelium and act on the adjacent smooth muscle cells to induce 
relaxation. NO and H2S are also produced in smooth muscle cells. NOS, NO synthase; 
CSE, cystathionine γ-lyase; COX-1, cyclooxygenase-1; AA, arachidonic acid; EDHF, 
endothelium-derived hyperpolarizing factor (Taken with permission from Wang R, 2009 
– See Appendix at the end). 
 
Recent literature shows that there is a close association between endothelial 
dysfunction, NO production and the risks of cardiovascular diseases. (Drexler, 1997; 
Taddei and 
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Salvetti, 2002).  Important functions of nitric oxide are as follows:  
1) Reducing vascular permeability and synthesis of monocyte and lymphocyte adhesion 
molecules.  
2) Decreases platelet aggregation, oxidation, inflammation, activation of thrombogenic 
mediators, cell growth, proliferation and migration. It inhibits proatherogenic and 
pro-inflammatory cytokines expression and favors fibrinolysis.  
3) Nuclear factor kappa-B (NFkB) inhibitor (I-kB) is also expressed by NO. All these 
factors reduce atherogenesis and its complication. For this reason, NO is considered 
the antiatherogenic molecule (Cooke JP et al., 1994; Baldwin A, 2001; Tak P, 
Firestein G, 2001; Libby P, 2001; Thurberg B, Collins T, 1998; Marx N, 1999,2001). 
 
Prostacyclin (PGI2): Prostacyclin belongs to the superfamily of eicosanoids (20 carbon 
atoms in molecule). It is an arachidonic acid derivative produced by the endothelial cells. 
It has a very short half-life of 3 minutes (Moncada et al. 1976). By increasing the 
intracellular cyclic adenosine monophosphate (cAMP), it acts as a potent platelet 
aggregation inhibitor (Rubin et al. 1990; Moncada et al. 1976). It is a powerful systemic 
and pulmonary vasodilator and is being used for the management of pulmonary arterial 
hypertension since 1980s (Boutet et. al., 2008). Moreover, prostacyclin seems to play an 
important role as antiproliferative, cytoprotective, fibrinolytic mediator and it reduces 
leukocyte trafficking (Jones, 1996). Signal transduction pathway of PGI2 is shown in 
Figure 4. 
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Endothelium-derived hyperpolarizing factor (EDHF): Besides NO and PGI2, the 
existence of another factor released from endothelium has emerged. This factor is known 
as EDHF. Most vascular beds show vasodilator responses despite of selectively blocking 
of NO and PGI2. Hyperpolarization of VSMC’s is absolutely essential for this relaxation 
and hence, this factor has been termed endothelium-derived hyperpolarizing factor 
(Feletou et. al., 1988; Taylor et. al., 1988; Chen et. al., 1988; Garland et. al., 1995; 
Edwards et. al., 1998; Busse et. al., 2002). Various vascular beds of different animals 
show that several relaxing factors released from endothelium, can hyperpolarize the 
underlying VSM through different mechanisms shown in figure 5 (Bellien et. al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R 
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Stress 
EDHF 
Endothelial Cells 
Hyperpolarization 
Hyperpolarization 
Smooth muscle cell 
Ca2+ 
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Figure 5: Schematic description of the main hyperpolarizing mechanisms mediated by 
EDHF. (Figure reproduced and modified from Bellien et. al., 2008) 
Endothelial receptors when bound to acetylcholine (ACh), bradykinin (BK) and 
substance P (SP) or an increase in wall shear stress promotes the synthesis of NO and 
could also enhance the production of EDHF. EDHF can then hyperpolarize the VSMC by 
three major pathways.  
1) EDHF can passively diffuse from the endothelium to activate calcium-activated 
potassium (KCa) channels of large conductance (BKCa) located on the smooth muscle 
cells thereby promoting the release of K+ and membrane hyperpolarization.  
2) EDHF can act in an autocrine manner facilitating the activation of small conductance 
(SKCa) and intermediate (IKCa) conductance directly mediated by Ca2+ activated K+ 
channels present on the endothelium and thus promotes first the hyperpolarization of the 
EC. Then, this hyperpolarization is believed to be transmitted electronically through the 
myoendothelial gap junctions (MEGJ) thereby inducing hyperpolarization of the adjacent 
VSMC. 
3) K+ released from the endothelial SKCa and IKCa channels into the myoendothelial 
space activates the Na+/K+ ATPase and the inward rectifying potassium channels (KIR) 
located on the smooth muscle cells promoting the release of K+ and subsequent 
hyperpolarization of these cells. Finally, the smooth muscle cells hyperpolarization 
decreases the open-state of voltage-gate Ca2+ channels lowering cytosolic Ca2+ and 
thereby provoking vasorelaxation (Bellien et. al., 2008). 
 
 
 11 
 
1.3 INTRODUCTION TO AMINO ACIDS, PEPTIDES & PROTEINS 
  Proteins are one of the most abundant biological macromolecules present in the 
cells and all parts of cells. They are present in great variety, have different molecular 
weights and have various biological functions. All proteins are composed of monomeric 
units of amino acids. Normally, all proteins are synthesized from 20 standard amino 
acids. Amino acids are defined as the molecules having both, an amino and carboxylic 
acid functional groups. They are very essential for life since they are also the building 
blocks of protein. In short, proteins are the polymers of amino acids with each amino acid 
residue joined to its neighbor by a strong covalent peptide bond. Here, the term residue 
means the loss of water molecules, when an amino acid is joined with another. Amino 
acids are important in being part of enzymes, coenzymes and also as a precursor for 
biosynthesis of various molecules of the body. (Wu, 2009) 
 
1.3.1 History of amino acids 
Asparagine was the first amino acid discovered when the French Chemists 
isolated it from asparagus (Vauquelin LN and Robiquet PJ, 1806). Cystine was 
discovered in 1810 (Wollaston WH, 1810), glycine and leucine in 1820 (Braconnot HM, 
1820) and cysteine in 1884 (Baumann E, 1884). The last of the 20 standard amino acids 
to be discovered was threonine in 1938 (Simoni et. al., 2002). 
 
1.3.2 General properties of amino acids 
All the 20 standard amino acids are α-amino acids i.e. they have both the carboxyl 
and amino functional group attached to the same carbon. The general structure of amino 
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acid is shown in Fig 6.  For all the standard amino acids except glycine, the α-carbon 
atom is bonded to 4 different functional groups namely: carboxylic acid, amino group, R 
group and a hydrogen atom. Thus, α-carbon atom is also a chiral center and 2 
enantiomers are possible. All molecules with chiral center are also optically active which 
means that they can rotate the plane-polarized light (l or levorotatory and d or 
dextrorotatory). Based on the special nomenclature system for simple sugars and amino 
acids, amino acids are categorized into D and L system. 
 
Figure 6: General structure of an amino acid. Above structure applies to all 20 standard 
amino acids with the exception of proline (cyclic amino acid). R-group attached to the α-
carbon atom is different in all amino acids. 
 
The 20 standard amino acids can also be classified on the basis of polarity. Amino 
acids with hydrophobic side groups include valine, leucine, isoleucine, methionine and 
phenylalanine. Asparagine, glutamic acid, glutamine, histidine, lysine, arginine and 
aspartic acid are the amino acids with hydrophilic side groups. Amino acids which are in 
between include glycine, alanine, serine, threonine, tyrosine, tryptophan, cysteine and 
proline. 
Amino acids, when dissolved in water can act either as an acid or as a base. When 
in solution, amino acids exist as a dipolar ions or zwitterions. Zwitterions can behave 
α-carbon atom 
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either as an acid by donating protons or as a base by accepting protons. Substances 
having this dual chemical property (amphoteric nature) are also known as ampholytes. 
 
1.3.3 Cardiovascular effects of amino acids 
Amino acids play a vital role in the functioning of central and peripheral nervous 
system. Some amino acids also have the capability to change the vascular tone (Katahira 
et. al., 1994). Intravenous (i.v.) administration of L-tryptophan, an essential amino acid 
has been shown to increase brain serotonin levels and can be used in several 
neuropsychiatric disorders (Wolf et al., 1984). Some amino acids serve as 
neurotransmitter or as a precursor for the synthesis of various neurotransmitters (Munro 
et al., 1986). Glycine, a non-essential amino acid derived from serine, acts as an 
inhibitory neurotransmitter in the CNS. Studies have revealed that glycine is protective 
against oxidative stress in several cardiovascular diseases (Hafidi et al., 2006). 
Antihypertensive action of L-serine has already been demonstrated by Mishra et al., 2008; 
Mishra et al., 2008. N-acetyl cysteine and taurine exert their beneficial effects by 
diminishing intracellular oxidative stress generation and glyco-oxidation (Anuradha et. 
al., 2009). Glycine and lysine prevent glycation. Recent studies also explore the 
beneficial effect of amino acids in diabetes and diabetic complications (Anuradha et al., 
2009). Central administration of taurine, L-alanine and gamma amino butyric acid 
(GABA) exerts an antihypertensive effect (Sgaragli et al., 1972). Tyrosine, a precursor 
for the synthesis of adrenaline and noradrenaline, when orally administered lowers blood 
pressure (Sved et al., 1979). At lower concentrations (25 and 50 mg/kg, i.p.), L- and D-
tryptophan both produced an increase in blood pressure (10-15mmHg). However, at 
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higher concentrations (100mg/kg, i.p.), L-tryptophan lowered the blood pressure of 
hypertensive rats by 30-35mmHg whereas D-tryptophan did not produce any fall in blood 
pressure (Wolf et al., 1984). They concluded that the lowering of blood pressure due to L-
tryptophan in hypertensive rat models cannot be entirely the effect of change in brain 
serotonin levels. Despite the in vivo studies, there are no in vitro studies to establish the 
mechanisms of the vasodilator response to L-tryptophan. The present study is an attempt 
to address this issue.  
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1.4 INTRODUCTION TO TRYPTOPHAN 
Tryptophan (Trp or W) is one of the 20 standard amino acids. Tryptophan was first 
isolated and reported in the beginning of last century (Hopkienns et al., 1901). It was 
isolated by hydrolysis of crude casein. It is also an essential or indispensible amino acid 
which means that mammals and humans cannot synthesize this amino acid de novo. 
Hence, it has to be obtained from the diet and is required by all living cells to synthesize 
protein (Leuchtenberger et al. 2005). As with other amino acids, only the L-stereoisomer 
of tryptophan is used in the synthesis of proteins and enzymes. However, D-tryptophan is 
at times found in natural peptides. Marine venom peptide, contryphan, contains D-
tryptophan (Pallaghy et al., 1999). 
 
1.4.1 General properties of tryptophan 
Aromatic amino acids include tryptophan, tyrosine and phenylalanine. The 
chemical formula of tryptophan is C11H12N2O2. It is a white crystalline solid, odourless 
and slightly bitter in taste with the molecular weight of 204 g/mole. Tryptophan is semi-
polar in nature. Thus, it is not very soluble in water (11.4 g/L at 25°C). However, it is 
more soluble in hot water, hot alcohol and solutions of dilute acid or of alkali hydroxides. 
Tryptophan is unique since it has an indole functional group that is not present in other 
amino acids. The structure of L-tryptophan is shown in Figure 7. 
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Figure 7: Structure of L-tryptophan 
 
1.4.2 Nutritional source of L-tryptophan 
Tryptophan is one of the least abundant amino acid found in dietary proteins. It 
can be obtained from chocolates, mangoes, dried dates, yogurt, cottage cheese, eggs, fish, 
poultry, sesame, chickpeas, sunflower seeds, pumpkin seeds, spirulina, and peanuts. 
Tryptophan constitutes only 1–1.5% of the amino acids present in casein, ovalbumin, and 
most meats (McCarthy et al., 1968). On the contrary, α-lactalbumin which is a minor 
milk protein is found to contain 6% tryptophan (Markus et al., 2002). 
 
1.4.3 Biosynthesis of L-tryptophan in plants and microorganisms 
Plants, fungi and microorganisms produce L-tryptophan by shikimic acid pathway 
(Herrmann and Weaver, 1999). Chorismate produced from shikimic acid pathway is 
condensed with glutamine to form anthranilate. The latter is then phosphoribosylated 
with phosphoribosylpyrophosphate (PRPP). Subsequent to ring opening of the ribose 
moiety and reductive decarboxylation, indole-3-glycerinephosphate is synthesized. The 
latter in turn is condensed with glyceraldehyde 3-phosphate to indole. In the final step, 
indole and serine are condensed in presence of tryptophan synthase to produce tryptophan 
(Radwanski et al., 1995). Large-scale industrial production of tryptophan is also 
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biosynthetic. It is based on the fermentation of serine and indole using E. coli in the 
presence of enzyme tryptophan synthase (Ikeda, 2002). The simplistic diagram of the 
biosynthetic pathway of L-tryptophan is shown below (Fig 8). 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Simplistic diagram of the biosynthesis of tryptophan by shikimic acid pathway 
in plants and micro-organisms (Figure 8 reproduced and simplified from Radwanski et 
al., 1995). 
 
1.4.4 Absorption of tryptophan from G.I.T 
Humans derive L-tryptophan from their diet. It is required by the body for the 
synthesis of various proteins. Being semi-polar, tryptophan is easily absorbed from the 
stomach. Following absorption into the blood, tryptophan undergoes first-pass 
metabolism in liver by the enzyme tryptophan dioxygenase (TDO). Thus, only a part of 
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ingested tryptophan actually enters the systemic circulation. Diet rich in proteins increase 
the plasma concentration of tryptophan. Under fasting conditions, tryptophan is released 
to a certain extent from reservoirs in tissue or circulating proteins. 
 
1.4.5 Plasma concentration of tryptophan 
The plasma concentration of amino acids differs in various physiological and 
pathological states. Disease conditions, postprandial, postabsorptive, exercise, starvation 
and injury can cause variation in the total and free plasma amino acid levels in the body. 
The average total plasma concentration of tryptophan in normal volunteers (n = 100) after 
overnight fasting was found to be 44 ± 7 μmole/L (Cynober, 2002).  
 
However, a significant difference in total plasma concentration of tryptophan in 
Sprague-Dawley rats (180 – 240 gm) was observed in control and fasting states as 
compared to humans. Plasma concentration of tryptophan in control and fasting states 
was found to be 90 – 117 μM and 76 – 125 μM respectively. Fasting states was defined 
as deprived of food but not water for 24 h (Knott et al., 1972). There was a significant 
increase in free plasma tryptophan levels in control and fasting states in Sprague-Dawley 
rats. 
    
1.4.6 Regulation of free plasma tryptophan levels 
Tryptophan is the only amino acid which exists in equilibrium between the 
albumin-free and albumin-bound state in the peripheral systemic circulation 
(McMenamy, 1965). Under resting conditions, tryptophan is almost 90% bound to 
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albumin which makes tryptophan-albumin complex almost impossible to cross the blood 
brain barrier (BBB). The remaining 10% of free tryptophan in plasma is actively 
transported across the BBB and enters the brain (Madras et al., 1974).  
 
One of the factors which play a very important role while estimating free plasma 
concentration of tryptophan is the presence of non-esterfied fatty acids (NEFAs). NEFAs 
compete with tryptophan for binding to albumin, and high concentration of NEFAs 
displace tryptophan from albumin-tryptophan complex (Curzon et al., 1973) leading to an 
increase in plasma free concentration of tryptophan (Chaouloff et al., 1986; Blomstrand 
et al., 1989). An increase in the level of NEFAs can be due to activation of sympathetic 
nervous system activity resulting from sustained exercise (Fernstrom et al., 2006). 
Lipolysis induced by activation of β-adrenoceptors also increases the levels of NEFAs 
(Ranallo et al., 1998). Drugs such as benzodiazepines (Muller et al., 1975) and clofibrate 
can also increase the plasma levels of NEFA (Spano et al., 1974). One might expect that 
the rise in brain tryptophan levels is because of an increase in free plasma concentration 
of tryptophan following NEFA elevation. However, latest experiments have just yielded 
contradictory results (Fernstrom et al., 2006). Dissociation of tryptophan-albumin 
complex in the cerebral microvascular system is an important factor for the increase in 
free tryptophan levels in the brain (Pardridge, 1990;1998). It is still unclear whether total 
or free plasma tryptophan levels are important for the rate of uptake of tryptophan in 
brain. 
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1.4.7 Transport of tryptophan into the brain 
For any substance to enter brain, it must cross the BBB. Since tryptophan is not 
highly lipophilic, passive diffusion of tryptophan through BBB is not possible. A 
competitive transporter that is shared with several large neutral amino acids (LNAAs) is 
responsible for the movement of tryptophan across BBB in rats (Fernstrom, 1983; 
Pardridge, 1977; Oldendorf et al., 1976) and humans (Hargreaves et al., 1988). This 
transporter is known as LAT1 or L -type amino acid transporter. LAT1 in BBB has more 
affinity for amino acids than L-type amino acid transporter in other tissues (Pardridge, 
1983). Also LAT1 is expressed more in BBB than in other tissues (Boado et al., 1999). 
Thus, increase in plasma concentrations of LNAAs will result in competition of amino 
acids including tryptophan for LAT1. Since, tryptophan is low compared to other 
LNAAs, it will lead to decrease in rate of uptake of tryptophan into brain (Fernstrom, 
2005). Mechanisms such as hemodynamics of cerebral microvasculature (Pardridge, 
1990), kinetics of tryptophan transport into brain, alteration in protein metabolism in the 
brain and alteration in the rate of efflux of tryptophan from brain play an important role 
in the regulation of tryptophan levels in the brain (Kennett, 1986; O’Kane, 2003). 
  
1.4.8 Metabolism of L-tryptophan 
In humans, ingested tryptophan undergoes first-pass hepatic metabolism in the 
liver by enzyme TDO. This enzyme, found only in liver, has the capacity to irreversibly 
cleave tryptophan’s indole ring to form N-formylkynurenine. Indoleamine 2,3-
dioxygenase (IDO) is another enzyme which has the potential to break the indole ring. It 
is active at tryptophan concentrations present in the blood and has Km value (26 µM) 
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much lower than that of TDO (45 µM) (Yamazaki et al., 1985; Shimizu et al., 1978). 
TDO is specific for the L-isomer of tryptophan (Tanaka and Knox, 1959), while IDO 
metabolizes a wide variety of compounds (L- and D-tryptophan; serotonin; melatonin). 
The latter is also found in all extra-hepatic tissues (Yamazaki et al., 1985), including 
brain (Kwidzinski et al., 2005).  The hepatic N-formylkynurenine generated by TDO is 
metabolized to L-kynurenine, kynurenic acid, xanthurenic acid, quinolinic acid, 
nicotinamide adenine dinucleotide (NAD), and, ultimately to carbon dioxide and water. A 
similar kynurenine pathway exists in brain (Guidetti et al., 1995) with its metabolites 
resulting in several neurological effects. Quinolinic acid, an N-methyl-D-aspartate 
(NMDA) agonist has neurodegenerative effects. (Stone and Perkins, 1981). Kynurenic 
acid, a glutamate receptor antagonist has shown to possess neuroprotective effects 
(Perkins and Stone, 1982).  Kynurenic acid also results in the inhibition of striatal 
dopamine release (Rassoulpour et al., 2005). Kynurenine has an ability to stimulate 
neuronal growth and development (Dong-Ruyl et al., 1998). Nicotine adenine 
dinucleotide (NAD) formed from this pathway also acts as a cofactor in various 
enzymatic reactions. IDO uses molecular oxygen and superoxides (O2-) as substrates and 
thus acts as an anti-oxidant.  
 
1.4.9 Metabolism of the tryptophan in CNS 
As free tryptophan is transported across BBB and into the brain, several 
metabolites are formed from different metabolic pathways in the brain. Serotonergic 
neurons and mast cells convert tryptophan into serotonin and its metabolites. In 
astrocytes, microglial cells, macrophages and dendritic cells, tryptophan undergoes 
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kynurenine and kynurenic acid metabolism. In pinealocytes, tryptophan undergoes 
metabolism into melatonin (Ruddick et al., 2006). Tryptophan metabolism in 
serotonergic neurons is shown below (Fig 9). 
 
Figure 9: Metabolism of tryptophan in serotonergic neurons. Tryptophan is transported 
from extracellular fluid into the neuron by the tryptophan transporter. Tryptophan 
hydroxylase 2, a rate-limiting enzyme located in the cytoplasm of the neuronal cell body, 
hydrolyses tryptophan to 5-HTP using O2 and BH4. Aromatic L-amino acid 
decarboxylase in presence of co-factor P5P, converts 5-HTP into 5-HT. Serotonin can 
either a) be converted into its metabolites 5-HIA and ultimately 5-HIAA in presence of 
the flavoprotein enzyme monoamine oxidase B and aldehyde dehydrogenase 
respectively, or b) be stored in synaptic vesicles with the help of VMAT2 and released on 
stimulation, or c) uptake of released serotonin into the neurons can take place with the 
help of SERT (O2- Oxygen, BH4- tetrahydrobiopterin, 5-HTP- 5-hydroxytryptophan, 5-
HT- 5-hydroxytryptamine, P5P- Pyridoxal-5’-phosphate, 5-HIA- 5-hydroxyindole 
acetaldehyde, 5-HIAA- 5-hydroxyindoleacetic acid, SERT- Serotonin transporter, 
VMAT2- Vesicular monoamine transporter 2, SBP- serotonin-protein binding), SSRI- 
Selective serotonin reuptake inhibitor. 
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1.5 Importance of L-tryptophan 
L-tryptophan, being an essential amino acid cannot be synthesized by humans or 
by other mammals. It acts as a building block for protein synthesis, L-tryptophan is the 
precursor of serotonin, a neurotransmitter. Serotonin plays an important role in the 
motility of gut, control of appetite, mood and anger (Berger et al., 2009). Serotonin also 
aids in sleep and general metabolism. Aggression and depression appear to be related to 
an imbalance of serotonin or other neurotransmitters in brain (Ryding et al., 2008). 
Serotonin can be converted to melatonin, a neurohormone, which is important in the 
regulation of circadian rhythms of various biological functions (Altun et al., 2007). 
Melatonin is known to be a powerful antioxidant that protects mitochondrial and nuclear 
DNA (Hardeland, 2005; Reiter et al., 2001). Niacin is synthesized from tryptophan via 
the kynurenine pathway. Biosynthesis of kynurenines in the CNS has significant effects 
on the physiology and behavior. Altered kynurenine metabolism is associated with AIDS 
related dementia (Guillemin et al., 2005), Huntington’s (Carlock et al., 1995) and 
Alzheimer’s disease (Guillemin et al., 2002; 2003; 2005). Auxin, a plant growth hormone 
is also synthesized from tryptophan. L-tryptophan is available as an over-the-counter 
(OTC) drug in Canada for use as a brain calming agent. 
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CHAPTER 2. HYPOTHESIS AND RATIONALE 
 
2.1 Rationale for the present study 
Ingestion of dietary proteins and gluconeogenic amino acids improves renal 
hemodynamics in several animal models and humans (Castellino et al., 1986; Daniels and 
Hostetter, 1990).  The effects of these amino acids on other vascular beds have not been 
examined.  N-octanoyl serine, a phospholipid intermediate isolated from bovine brain, 
evokes endothelium-dependent but nitric oxide (NO) and cycloxygenase (COX)-
independent vasodilatation in isolated rat blood vessels  (Milman et al., 2006).  Recent 
studies from our laboratory have established that a non-essential amino acid, L-serine, per 
se evokes endothelium-dependent but NO and COX-independent vasodilatation in rat 
mesenteric arterioles via selective activation of EDHF (Mishra et al., 2008).  In addition, 
acute L-serine infusion leads to a dramatic dose-dependent fall in BP.  This effect of L-
serine is much higher in both L-NAME-induced hypertensive rat and SHR models.  In 
contrast to L-serine, infusion of glycine, a metabolite of L-serine, reduces BP in 
normotensive rats but paradoxically evokes pressor responses in both L-NAME-induced 
hypertensive and SHR strains (Mishra et al., 2008). The significance and importance of 
the cardiovascular protective and the antihypertensive effects of taurine, a sulphur 
containing amino acid, known for a long time, has been reinforced by recent reviews on 
this subject (Yamori et al., 1996; Xu et al., 2008). More recently, another amino acid, 
glutamic acid, rich in vegetable proteins, has received greater attention since it reduces 
BP in humans (Stamler et al., 2009).   These recent studies led us to the conclusion that 
besides endogenous vasoactive peptides such as atrial natriuretic peptide (ANP), 
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bradykinin and CGRP, amino acids in circulation, could also contribute to the regulation 
of vascular smooth muscle (VSM) tone, total peripheral resistance (TPR) and BP.  These 
observations have led us to examine the effects of different amino acids on vascular 
reactivity changes as major focus of our research. 
 
While acute intravenous infusion of L-serine leads to dramatic fall in BP, the oral 
feeding of L-serine, being polar, is associated with less dramatic effect on BP because of 
its reduced absorption. To overcome this problem, we looked at options of coupling L-
serine with other amino acids that would also promote fall in BP so these agents could be 
administered as orally active di or tripeptide to reduce cardiovascular disease (Erdmann 
et al., 2008).  With this as the goal, other investigators have combined two amino acids, 
L-tryptophan (W) and histidine (H) as a dipeptide (W-H) and tested its effect on in vitro 
preparation such as rat aortic rings. W-H exerted endothelium-independent vasodilatation 
in rat aortic rings (Tanaka et al., 2008).  This effect of W-H is dose-dependent and it is 
suggested to act as a Ca2+ channel antagonist since it potentiated the blockade of 
potassium chloride (KCl) evoked vasoconstrictor responses by verapamil in this 
preparation (Tanaka et al., 2008).  It is possible that this effect of W-H could be due to its 
endogenous conversion of both L-tryptophan and histidine to serotonin (5-HT) and 
histamine respectively. Thus these biogenic amines in turn could mediate their vascular 
responses.  In view of the potential bronchoconstrictor problems associated with 
conversion of histidine to histamine, a combination of L-serine and L-tryptophan is 
considered by our laboratory as a potential dipeptide that would provide cardiovascular 
protection.  Moreover, such a combination we hypothesize would lead to endothelium-
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dependent (L-serine-mediated) and endothelium-independent (L-tryptophan-induced 
blockade of Ca2+ channels) vasodilator/antihypertensive effect associated with the oral 
administration of such a serine-tryptophan combination treatment as an orally active 
dipeptide.  
 
Before preparing and examining the effect of such a dipeptide, either as S-W, or 
W-S, it is important to examine the acute effects of L-tryptophan in parallel with L-serine. 
An earlier report suggested that L-tryptophan exerts an antihypertensive effect in SHR 
and this is suggested to occur by its conversion to serotonin in the brain (Sved et al., 
1982). However, studies by others proposed that the effect seen with L- but not D-
tryptophan cannot be explained simply by the changes in brain serotonin levels and that 
other peripheral mechanisms could contribute to its antihypertensive effect (Wolf et al., 
1984; 1984).  Others have concluded that the proposed antihypertensive effect of L-
tryptophan is due to centrally mediated changes in several bioactive amines and 
angiotensin II (Fregly et al., 1988).   However, this controversy remains to be settled.  It 
should be pointed out that many of these BP measurement studies have been conducted 
using either the tail cuff methodology or by direct catheter recording from arteries 
cannulated in anaesthetized rats. Recent studies using radiotelemetry recording of BP 
measurement in conscious freely moving rats do not validate the changes reported by tail 
cuff or recording in anaesthetized rats as these methodologies provide false positive 
results for the changes in BP (Balakrishnan et al., 1998).  While in-vivo studies with L-
tryptophan would be important, first, it is necessary to demonstrate the direct vascular 
effects of L-tryptophan.  It is known that serotonin which is biosynthesized from L-
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tryptophan is a potent vasoconstrictor in several vascular beds (Watts, 2002).  Most 
vascular beds are endowed with the enzymatic machinery to generate serotonin from L-
tryptophan. It is considered that bioconversion to 5-HT is the major mechanism for L-
tryptophan induced changes in BP in hypertensive rats.  While elevated plasma 5-HT 
level and arterial hyper-responsiveness to 5-HT has been demonstrated in hypertensive 
rats, studies have also shown that administration of serotonin reduces BP in hypertensive 
rat models (Centurion et al., 2004; Terron et al., 2007; Diaz et al., 2008).  In addition, 
vascular 5-HT2B and 5-HT7 receptor activation would promote vasodilatation to 5-HT in 
some arteries and veins have also been suggested (Ellis et al., 1995; Terron, 1997; Ishine 
et al., 2000).  Given this complexity, it is important to examine the direct vascular effects 
of L- tryptophan and D-tryptophan and establish whether there are differences in 
vasoconstrictor and/or vasodilator responses to L- and D-tryptophan and the likely role 
played by endothelium in mediating these effects. In addition, whether these responses 
are mediated by its conversion to 5-HT would be an important issue to consider in the 
proposed experimental plan.  Based on the above, the following working hypotheses have 
been formulated.  
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2.2 Working hypothesis 
L-tryptophan but not its D-isomer, will evoke vasoconstrictor and vasodilator 
responses that are mediated by its conversion to serotonin. Serotonin antagonists will 
block these responses to L-tryptophan.  
The vasoconstrictor responses to L-tryptophan are mediated by the activation of 
vascular 5-HT2A receptors. The vasodilator responses are mediated via recruitment of 
both endothelium-derived relaxing factors (EDRF) and activation of processes on 
vascular smooth muscle cells that are endothelium-independent and this is via 
recruitment of another subtype of 5-HT receptors.  
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CHAPTER 3. MATERIALS AND METHODS 
 
3.1 Animals 
The protocol for the animal studies employed in the present study was approved 
by our University Review Committee and it conformed to the Guide for the Care and Use 
of Laboratory Animals stipulated by the Canadian Council on Animal Care and the 
National Institute of Health (NIH) publication No. 85: 23, 1996. Male Sprague-Dawley 
rats at 11 weeks were obtained from Charles River, (St Constant, Quebec, Canada). The 
animals were allowed to recover for 1 week before the experimental protocol was 
initiated. All rats were kept under standard conditions with a light/dark cycle of 12 hrs 
and a constant temperature of 22 ± 1ºC. The rats were fed ad libitum with food pellets 
(Purina Rat Chow) and tap water. Experimental protocol was initiated only when the rats 
were 12-14 weeks old. 
 
3.2 Materials 
Chemicals and reagents used in these experiments are described as follows. 
Acetylcholine (ACh), barium chloride (BaCl2), indomethacin, L-tryptophan methyl ester 
hydrochloride, D-tryptophan methyl ester hydrochloride, ouabain, phenylephrine 
hydrochloride (PE), NG nitro L-arginine methyl ester (L-NAME), glibenclamide, 
ketanserin tartarate, tetraethylammonium bromide (TEA), sodium chloride, sodium 
bicarbonate, calcium chloride, magnesium chloride hexahydrate, dextrose, potassium 
dihydrogen phosphate  and methoxamine hydrochloride were purchased from Sigma-
Aldrich Chemical Co., Oakville, ON., Canada. 
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3.3 Methods 
3.3.1 Choice of preparation 
The perfused rat mesenteric vascular bed maintained at a constant flow rate 
(5mL/min) is a sensitive vascular preparation that consists of the changes in VSM tone 
arising from both conduit (superior mesenteric artery) artery and its primary, secondary, 
and tertiary branches arising in this arterial cascade. It is known that 25% of the cardiac 
output flows through the splanchnic vascular bed and the mesenteric vascular cascade is 
an important and major cardiovascular circuit.  The vascular reactivity changes occurring 
in this vascular bed are considered to serve as a representative response for resistance 
type vessels (Mulvany, 1993). Our laboratory is well versed in setting up this ex-vivo 
preparation and repeated responses to both vasoconstrictor and vasodilator agonists could 
be determined in the same vascular bed (Moazed et al., 2009; Shastri et al., 2002; 
Misurski et al., 2001; 2001; 2002). Therefore, it was decided to utilize this preparation to 
compare the responses to L- and D-tryptophan. 
 
3.3.2 Surgical procedure for isolation of rat mesenteric vascular bed 
Experiments were performed only when animals were 12 weeks old. Rats were 
anesthetized with thiopental sodium (100 mg/kg, i.p.), coeliotomy was performed by a 
mid-line incision and the heart was isolated. Without much delay, the superior mesenteric 
artery was identified and cleared of any adherent tissue using a cotton swab. Using 
curved forceps, two pieces of sutures were placed beneath the superior mesenteric artery 
at the level of the T-junction where the superior mesenteric artery branches off from the 
abdominal aorta. This was followed by a small incision made at the T-junction and the 
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superior mesenteric artery was cannulated with polyethylene tubing fitted on to a 20 
gauge needle. A small amount of Krebs buffer was pushed into mesenteric vascular bed 
to remove blood clots. The mesenteric vascular bed was then cut carefully along the line 
of the intestinal tract in such a way that the bed was not stretched and there was minimal 
loss of arterioles. The entire bed was isolated from the gastrointestinal tract, and placed in 
a warm (37 ± 1ºC) Krebs solution. The mesenteric vascular bed was then transferred and 
connected to the perfusion apparatus (Misurski et al., 2000; Shastri et al., 2001). 
 
3.3.3 Perfusion of mesenteric vascular bed 
The mesenteric vascular bed was perfused via cannula with the Krebs buffer 
solution (pH 7.4) by means of a pump, at a constant flow rate of 5 ml/min. The 
composition of the Krebs buffer solution (in mM) was: NaCl 118, KCl 4.7, MgCl2.6H2O 
1.2, CaCl2.2H2O 1.8, KH2PO4 1.2, NaHCO3 25 and Glucose 11.1. The buffer was 
continuously oxygenated using carbogen (95% O2 oxygen + 5% CO2) and maintained at 
a steady temperature 37ºC with the thermocirculator (from Harvard apparatus). An air 
pocket was incorporated in the route for preventing the air-bubbles from entering the 
mesenteric bed. Air bubbles are known to cause endothelium denudation and can result in 
variation of responses to pharmacological agents (Misurski et al., 2000; Shastri et al., 
2001). 
 
3.3.4 Recordings of variations in perfusion pressure to various agonists 
and antagonists 
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The variations in perfusion pressure in response to agonists and antagonists were 
measured using a strain gauge pressure transducer placed in the circuit. A chart program 
(Chart V5.5.6) using a PowerLab/8SP Series system (AD Instruments Pty. Ltd., 
Castlehill, NSW, Australia) was setup to visualize the changes in perfusion pressure on 
the computer. The pressure transducer, attached to the PowerLab was placed in the circuit 
of the flow of Krebs buffer to record the changes in perfusion pressure. The pressure 
transducer was calibrated each time using a sphygmomanometer before the start of the 
experiment. 
 
3.3.5 Experimental procedure 
3.3.5.1 Equilibrium period for mesenteric vascular bed 
Once the mesenteric bed was hooked to the system, it was allowed to equilibrate 
for 1 h with normal Krebs buffer to attain steady basal perfusion pressure. Mesenteric 
vascular beds having basal perfusion pressure of above 20 mmHg and below 30 mmHg 
were used in the experiments. Lower basal perfusion pressure indicated that the 
mesenteric bed was not isolated properly and the level of resistance developed in the 
vascular bed was inadequate. Very high perfusion pressure indicated that either the suture 
was tied so firmly to the cannula that it obstructed the flow of Krebs buffer or that there 
was a blood clot in the mesenteric bed. Then, two bolus doses of PE (80 μmol/L), a non-
selective α1 agonist, were given in succession to ensure that equipotent constrictor 
responses were obtained and that the tissue had attained the required equilibrium to 
respond to exogenous agents. 
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3.3.5.2 Experimental procedure for concentration-response curves to 
vasoconstriction effects of tryptophan 
Tryptophan, a semipolar compound is sparingly soluble in water (11.4 g/L at 
25°C). To enhance the solubility of tryptophan, we decided to use its methyl ester 
hydrochloride salt. No differences were seen between the effects of the methyl ester 
hydrochloride salt form and the free amino acid (Wolf et al., 1984). From now onwards, 
L- and D-tryptophan methyl ester hydrochloride will be simply noted as L- and D-
tryptophan respectively. The experiments were performed with two tissues isolated from 
two Sprague-Dawley rats and were perfused at the same time. Log dose of L- and D- 
tryptophan (0.01, 0.03, 0.1, 0.3, 1, 3 and10 µmol) within the pharmacological range were 
then injected as bolus dose of 0.5ml. Sufficient time (45 min-1 hr) was given for recovery 
of tissue after completion of the concentration-response curves to each agonist prior to 
constructing the second concentration-response curve in the same tissue. No 
desensitization of mesenteric bed was observed while taking the concentration-response 
curve to the next agonist. This was verified by repeating the concentration-response 
curves to the same agonist. Taking either D- or L- tryptophan panel first did not affect the 
results of the concentration-response curve. To elucidate the mechanism of contractile 
response, the responses to L-tryptophan were performed in the presence and absence of 
increasing concentration of ketanserin tartarate. Literature review did not reveal the dose 
of ketanserin used previously in mesenteric vascular bed. After performing a series of 
preliminary experiments, the dose of ketanserin was titrated to 2 nM, 5 nM and 10 nM. 
Ketanserin tartarate was dissolved in krebs buffer, adjusted to pH 7.4 and was perfused 
through mesenteric bed for 30 minutes. After perfusion of one concentration of 
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ketanserin tartarate, concentration-response curves to same doses of L-tryptophan (0.01, 
0.03, 0.1, 0.3, 1, 3 and 10 µmol) were obtained. This procedure was repeated with 
different doses of ketanserin. Parallel studies were performed to establish the competitive 
blockade of 5-HT evoked responses by the same concentration of ketanserin.    
 
3.3.5.3 Experimental procedure for concentration-response curves to 
vasodilatation effects of tryptophan 
Methoxamine (30 µM), an α1 specific agonist was perfused through mesenteric 
bed for 20 min, until a steady constriction level was obtained. Phenylephrine, another α1 
selective agonist was not used for constriction since a steady tonic response to this 
agonist was difficult to attain. Once the steady state tonic PP was attained, the presence 
of endothelium was always verified by a bolus dose of acetylcholine (ACh 300 pmol). 
The presence of intact endothelium produces 85-95% vasodilatation to ACh. Then, 
concentration-response curves to L- and D- tryptophan (0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 
30 µmol) were obtained. Sufficient recovery period (45 min to 1 hr) was given between 
the two concentration-response curves. Desensitization of tissue was verified by 
obtaining concentration-response curves to L- and D- tryptophan more than once in the 
same tissue. The order of conducting concentration-response curves to L- and D- 
tryptophan did not affect the results. Entire set of concentration-response curves to 5-HT 
was also taken in constricted mesenteric vascular bed. 
 
With a view to characterize the mechanism of vasodilator response, ketanserin 
tartarate (5nM), a specific 5-HT2A blocker, was added to Krebs buffer containing 
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methoxamine and perfused through mesenteric bed for 20 min. Concentration-response 
curves to L-tryptophan were compared in the presence and absence of ketanserin.  
 
  To determine whether vasodilator responses to L-tryptophan are mediated through 
endothelium, almost all relaxing factors derived from endothelium were blocked by 
employing a combination of L-NAME (100 µM), indomethacin (10 µM), BaCl2 (50 µM) 
and ouabain (10 µM). These compounds were dissolved in Krebs buffer containing 
methoxamine and were perfused through mesenteric bed for 20 min after taking the 
control responses. Concentration-response curves to L-tryptophan were again taken in the 
presence of these inhibitors. 
 
Individual experiments were carried out with each of TEA (non-selective 
potassium channel blocker) (0.5 mM), BaCl2 (inward-rectifying potassium channel 
blocker) (50 µM), ouabain (Na+-K+ ATPase pump inhibitor) (5 µM) or glibenclamide 
(KATP channel inhibitor) (10 µM) after taking a control concentration-response curve to 
L-tryptophan. These compounds were dissolved in Krebs buffer and were perfused 
through mesenteric bed for 20 minutes. Concentration-response curves to L-tryptophan 
were again taken in the presence of these inhibitors. 
 
To verify, whether the vasodilator responses to L-tryptophan were mediated by 
inhibition of voltage-operated calcium channels, a concentration-response curve to L-
tryptophan was determined in the presence of KCl (100 mM) induced constriction. 
Instead of methoxamine, KCl (100mM) was perfused through mesenteric bed for a 
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minimum of 20 min or more until the elevated perfusion pressure reached a steady state. 
Then, concentration-response curves to L-tryptophan were determined. 
 
 
3.3.5.4 Procedure for endothelium denudation in perfused mesenteric 
vascular bed. 
Initially, the concentration-response for ACh-evoked vasodilatation was 
determined in methoxamine (30 μM) constricted mesenteric vascular beds. Subsequently, 
endothelium was denuded by perfusing sodium deoxycholate (1.8 mg/mL) for 15 seconds 
followed by injecting air bubbles in the perfusate for a period of 5 min. The mesenteric 
bed was perfused with normal Krebs buffer for 1 hr and was allowed to recover. After the 
recovery period, the absence of endothelium was ascertained by confirming the lack of 
vasodilator responses to ACh (dose: 0.1 to 300 pmol) (85-95% inhibition). 
Concentration-response curves to L-tryptophan were determined prior to and after 
endothelium denudation in methoxamine constricted state. 
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3.4 Statistical Analysis 
The vasoconstrictor and vasodilator responses to L- and D- tryptophan were 
determined were determined in Sprague-Dawley rats. Data points are the mean ± 
Standard error of the mean (SEM) for n ≥ 4. Graphpad prism (Version 5.0) was used to 
perform the statistics. Differences between the means of vasoconstriction and 
vasodilatation responses to L- and D- tryptophan were compared by t-test. Differences 
between the means of control and each of ketanserin (2nM, 5nM and 10nM) were 
compared by ANOVA test (n = 5). All other comparisons between control and various 
compounds (n ≥ 4 ) used to block the vasodilator responses to L-tryptophan were also 
compared by t-test. The differences were considered significant (*) only when p < 0.05. 
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CHAPTER 4. RESULTS 
 
4.1 Vasoconstrictor effect of tryptophan 
Vasoconstrictor responses to L- and D- tryptophan were concentration-dependent 
at basal perfusion pressure in mesenteric vascular bed. L-tryptophan evoked 
vasoconstrictor responses were higher than those from D-tryptophan. The representative 
data from a single experiment that compares the response to L- and D- tryptophan were 
presented in Fig 10 and 11. Table 1 shows the changes in perfusion pressure for each 
dose of L- and D- tryptophan. Each data point was expressed as the mean ± SEM of 5 
observations. Emax values of L- and D-tryptophan were observed to be 141 ± 7 and 127 ± 
8 (in mmHg) respectively. EC50 values for L- and D-tryptophan were observed to be 0.79 
± 0.30 and 0.25 ± 0.12 (in µmol) respectively (shown in Table 2). The leftward shift of 
the concentration-response curves to D-tryptophan as compared to L-tryptophan was 
observed (Fig 12). D-tryptophan was found to be more potent (from the EC50 values) than 
L-tryptophan. There was no significant difference in Emax values between the two stereo-
isomers of tryptophan. The rightward shift of the concentration-response curve to L-
tryptophan in the presence of different concentrations of ketanserin was observed (Fig 
13). This rightward shift indicates that ketanserin (at various concentrations) 
competitively inhibits the vasoconstriction effects of L-tryptophan. Table 3 contains data 
for each dose of L-tryptophan expressed as means ± SEM in presence of different 
concentrations of ketanserin. EC50 and Emax values of L-tryptophan in presence of varying 
doses of ketanserin are shown in Table 4. 
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Figure 10: A representative experiment that shows the concentration-dependent 
vasoconstrictor responses to L-tryptophan in the perfused rat mesenteric vascular bed. 
Numbers in graph indicate increasing concentration of L-tryptophan. (1-7 corresponds to 
0.01, 0.03, 0.1, 0.3, 1, 3 and 10 µmol) Similar responses were reproduced in 7 other 
preparations. 
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Figure 11: A representative experiment that shows the concentration-dependent 
vasoconstrictor responses to D-tryptophan in the perfused rat mesenteric vascular bed. 
Numbers in graph indicate increasing concentration of D-tryptophan. (1-7 corresponds to 
0.01, 0.03, 0.1, 0.3, 1, 3 and 10 µmol) Similar responses were reproduced in 6 other 
preparations. 
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Table 1: Changes in perfusion pressure for each concentration of L- and D- tryptophan in 
isolated perfused rat mesenteric vascular bed. Data are expressed as mean ± SEM. N = 6. 
Dose (µmol) L-tryptophan response (mmHg) D-tryptophan response (mmHg) 
Baseline 29 ± 2 31 ± 1 
0.01 31 ± 1 33 ± 1 
0.03 35 ± 2 41 ± 2 
0.1 40 ± 2 52 ± 2 
0.3 64 ± 6 94 ± 6 
1 99 ± 8 112 ± 5 
3 132 ± 6 127 ± 8 
10 141 ± 5 127 ± 9 
 
Table 2: Comparison of EC50 and Emax values between L- and D- tryptophan in isolated 
perfused rat mesenteric vascular bed. Data are expressed as mean ± SEM. N = 6. *p < 
0.05. 
 
Drug EC50 (µmol) Emax (mmHg) 
L-tryptophan 0.79 ± 0.30 141 ± 7 
D-tryptophan 0.25 ± 0.12* 127 ± 8 
 
 43 
 
Figure 12: The line graphs compare the concentration-response curves to L-tryptophan 
(○) and D-tryptophan (●) in isolated perfused rat mesenteric vascular bed. Each data point 
is expressed as mean ± SEM. N = 6. *p < 0.05. 
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Figure 13: The following line graphs represent concentration-response curves to L-
tryptophan in the presence of varying concentrations of ketanserin in isolated perfused rat 
mesenteric vascular bed. N ≥ 5 for all graphs.  
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Figure 13a: Control (○) vs Ketanserin 2 nM (●) 
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Figure 13b: Control (○) vs Ketanserin 5 nM (●)  
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Figure 13c: Control (○) vs Ketanserin 10 nM (●) 
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Figure 14: The bar diagram compares the constrictor responses to L-tryptophan in the 
presence of varying concentrations of ketanserin 2 nM, 5 nM and 10 nM.  Each data point 
expressed as mean ± SEM and N ≥ 5. (*p < 0.05). 
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Table 3: Changes in perfusion pressure for each concentration of L-tryptophan in the 
presence of varying concentration of ketanserin. The data are expressed as mean ± SEM. 
N ≥ 5. 
Dose of L-
tryptophan 
(µmol) 
Control  
(mmHg) 
Ketanserin 2nM 
(mmHg) 
Ketanserin 5nM 
(mmHg) 
Ketanserin 10nM 
(mmHg) 
0.0 26 ± 2 26 ± 2 26 ± 2 26 ± 2 
0.1 42 ± 2 41 ± 2 36 ± 1 35 ± 2 
0.3 70 ± 9 63 ± 6 56 ± 6 47 ± 3 
1 108 ± 7 96 ± 6 82 ± 5 74 ± 6 
3 127 ± 7 118 ± 6 106 ± 6 94 ± 8 
10 126 ± 7 128 ± 4 119 ± 8 117 ± 5 
30  128 ± 3 130 ± 4 119 ± 5 
 
Table 4: Comparison of EC50 and Emax values (expressed as mean ± SEM) of L-
tryptophan in presence of varying concentrations of ketanserin (Ket). N ≥ 5. *p < 0.05, **p 
< 0.01. 
Drug Control Ket 2nM Ket 5nM Ket 10nM 
EC50 (µmol) 0.43 ± 0.2 0.53 ± 0.2  0.91 ± 0.4* 1.20 ± 0.5** 
Emax (mmHg) 141 ± 6 128 ± 4 130 ± 4 119 ± 5 
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4.2 Vasodilator effects of tryptophan 
L- and D-tryptophan evoked concentration-dependent vasodilatation in 
methoxamine constricted perfused mesenteric vascular beds. A representative experiment 
that shows concentration-dependent vasodilator responses to L- and D- tryptophan are 
shown (Figure 15 and 16). Table 5 shows % vasodilatation for each dose of L- and D- 
tryptophan. Maximum vasodilatation (% Imax) values for both L- and D- tryptophan was 
found to be 87.5 ± 1.2 and 96 ± 1.5 (Table 6). IC50 values (in µmol) for L- and D-
tryptophan were found to be 2.78 ± 0.9 and 0.94 ± 0.3 respectively. The leftward shift of 
the concentration-response curves to D- tryptophan (as compared to L-tryptophan) was 
shown in Fig 17. Maximum vasodilatation responses to D-tryptophan were statistically 
significant as compared to L-tryptophan.   
 
The concentration-vasodilator response curves to L-tryptophan were also 
determined in the presence and absence of ketanserin (Fig 18). Table 6 shows the IC50 
and Imax values in the presence and absence of ketanserin (5nM). Figure 18 and table 6 
clearly suggest that 5-HT2A were not involved in the vasodilator response to L-
tryptophan. Fig 19a and Fig 19b compare the vascular effects of L-tryptophan and 5-
hydroxytryptamine (5-HT). L-tryptophan produced a dose-dependent fall in perfusion 
pressure while 5-HT evoked a vasoconstrictor effect as seen with an increase in perfusion 
pressure. Fig 20 shows the vascular effects of L-tryptophan in KCl (100 mM) induced 
constriction. A dose-dependent increase in perfusion pressure was observed.  
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The likely role of the relaxing factors from the endothelium contribute to the 
vasodilator effects of L-tryptophan were assessed by including a combination of 
inhibitors such as L-NAME (100 µM) + indomethacin (10 µM) + BaCl2 (50 µM) + 
ouabain (10 µM). Endothelium denudation was verified by the attenuation of 
vasodilatation responses to acetylcholine as shown in Fig 21. Fig 22 compares the 
concentration-response curve of L-tryptophan in the presence and absence of inhibitors of 
endothelium dependent relaxing factors. Apparently, there was no blockade of the 
vasodilatation response to L-tryptophan. To verify the above data, endothelium was 
denuded with an alternative technique using air and sodium deoxycholate. Fig 23 shows 
and compares the vasodilator responses to L-tryptophan in the presence and absence of 
endothelium. There was no significant block in the vasodilator responses to L-tryptophan 
in the absence of endothelium. 
 
Inclusion of the appropriate concentrations of either glibenclamide, a KATP 
blocker (10 μM); tetraethyl ammonium, a non-selective potassium channel blocker (0.5 
mM); ouabain, a Na+-K+ ATPase pump inhibitor (10 μM) or a Kir channel inhibitor, 
BaCl2 (50 μM) failed to affect the vasodilator responses to increasing concentration of L-
tryptophan in methoxamine preconstricted perfused mesenteric vascular bed (See Fig 24, 
25, 26 and 27). Our results clearly indicate that there was no block in the vasodilator 
response to L-tryptophan.  
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Figure 15: A representative experiment that shows concentration-dependent vasodilator 
responses to L-tryptophan in methoxamine constricted perfused rat mesenteric vascular 
bed. Numbers in graph indicate increasing concentration of L-tryptophan (1-8 
corresponds to 0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 30 µmol). Similar responses were 
reproduced in 12 other preparations. 
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Figure 16: A representative experiment that shows concentration-dependent vasodilator 
responses to D-tryptophan in methoxamine constricted perfused rat mesenteric vascular 
bed. Numbers in graph indicate increasing concentration of D-tryptophan (1-8 
corresponds to 0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 30 µmol). Similar responses were 
reproduced in 3 other preparations. 
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Figure 17: The line graphs compare concentration-vasodilator responses to L-tryptophan 
(○) and D-tryptophan (●)  in isolated rat mesenteric vascular bed. Each data point is the 
mean ± SEM. N = 4. *p < 0.05. 
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Table 5: % Vasodilatation for each concentration of L- and D- tryptophan. Each entry is 
the mean ± SEM. N = 4. 
Dose % Vasodilatation to L-tryptophan % Vasodilatation to D-tryptophan 
0.01 2 ± 1 2 ± 1 
0.03 3 ± 2 8 ± 3 
0.10 11 ± 4 15 ± 4 
0.30 13 ± 4 29 ± 6 
1.00 35 ± 5 50 ± 6 
3.00 48 ± 3 74 ± 4 
10.00 82 ± 1 88 ± 3 
30.00 91 ± 1 96 ± 2 
 
Table 6: IC50 and Imax values of L- and D-tryptophan. Comparison of IC50 values 
between L- and D-tryptophan. Each data is expressed as mean ± SEM. ¶N = 4 and ¶¶N=16. 
*p < 0.05. 
 
Drug IC50 (µmol) Imax (% Vasodilatation) 
L-tryptophan¶¶ 2.78 ± 0.9 87.5 ± 1.2 
D-tryptophan¶ 0.94 ± 0.3* 96 ± 1.5 
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Figure 18: Effect of (■) ketanserin (5 nM) on the vasodilator responses of (□) L-
tryptophan in methoxamine constricted isolated perfused rat mesenteric vascular bed with 
each data point is the mean ± SEM and N = 4. (*p < 0.05; **p < 0.01). 
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Table 7: IC50 and Imax values of L-tryptophan in presence and absence of ketanserin (5  
nM). N = 4.  
Drug IC50 (µmol) Imax (% Vasodilatation) 
Control 2.54 ± 0.6 85 ± 1 
Ketanserin (5nM) 1.59 ± 0.9 82 ± 2 
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Figure 19: Comparison of the vascular effects of L-tryptophan and 5-hydroxytryptamine 
(5-HT). Each data point is the mean ± SEM. 
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Figure 19a) L-tryptophan concentration-response curve in methoxamine induced 
constriction. L-tryptophan evokes concentration-dependent vasodilatation in MTX 
constricted isolated perfused rat mesenteric vascular bed. N = 4. 
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Figure 19b) 5-Hydroxytryptamine (5-HT) concentration-response curve in methoxamine 
induced constriction. 5-HT evokes concentration-dependent vasoconstriction in MTX 
constricted isolated perfused rat mesenteric vascular bed. N = 4. 
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Figure 20: Concentration-response curve to L-tryptophan in KCl (100mM) induced 
constriction in isolated perfused rat mesenteric vascular bed. Each data point is the mean 
± SEM and N = 4. 
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Figure 21: A line graph showing the attenuation of vasodilator responses to ACh after 
endothelium denudation in methoxamine constricted isolated perfused rat mesenteric 
vascular bed. Each data point is the mean ± SEM and N = 4. 
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Figure 22: Vasodilator effects of L-tryptophan in absence (○) and presence (●) of 
combination of L-NAME (100 µM), indomethacin (10 µM), BaCl2 (50 µM) and ouabain 
(10 µM) in methoxamine constricted isolated perfused rat mesenteric vascular bed. Each 
data point is the mean ± SEM and N = 4. 
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Figure 23: Vasodilator responses to L-tryptophan in presence and absence of 
endothelium in methoxamine constricted isolated rat perfused mesenteric vascular bed. 
Each data point is the mean ± SEM and N = 4. *p < 0.05. 
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Figure 24: Effect of glibenclamide (10µM) on vasodilator response to L-tryptophan in 
methoxamine constricted perfused mesenteric vascular bed. Each data point is the mean ± 
SEM and N = 4. *p < 0.05. 
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Figure 25: Effect of TEA (0.5 mM) on vasodilator response to L-tryptophan in 
methoxamine constricted isolated perfused rat mesenteric vascular bed. Each data point is 
the mean ± SEM and N = 4. *p < 0.05. 
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Figure 26: Effect of BaCl2 (50 µM) on vasodilator response to L-tryptophan in 
methoxamine constricted isolated perfused rat mesenteric vascular bed. Each data point is 
the mean ± SEM and N = 4. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Figure 27: Effect of ouabain (10 µM) on vasodilator response to L-tryptophan in 
methoxamine constricted isolated perfused rat mesenteric vascular bed. Each data point is 
the mean ± SEM and N = 4. *p < 0.05; **p < 0.01; ***p < 0.001. 
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CHAPTER 5. DISCUSSION 
 
5.1 Vasoconstrictor response to tryptophan 
The present investigation demonstrates that both L- and D-tryptophan evoke 
concentration-dependent (0.01 to 10µmol) increases in perfusion pressure of the 
mesenteric vascular bed. Most of higher organisms such as mammals recognize only the 
L-stereoisomer of amino-acid for protein synthesis and other functions. Experiments 
showed that L-tryptophan evoked slightly higher contractile response than D-tryptophan. 
Although, there was no significant difference in the maximum constrictor responses 
between the two isomers, EC50 values clearly indicate that D-tryptophan was more potent 
that L-tryptophan. 
 
To characterize the mechanism of contractile response, our first target was to 
block 5-HT receptors. As of now, 5-HT receptors have been classified into seven major 
subtypes (5-HT1-7) (Linder et al., 2007). From the literature, we found that 5-HT2A and 5-
HT2B receptors are the main contractile receptors in the rat renal artery. The 5-HT2B 
receptor is the primary contractile receptor in aorta. The 5-HT2A subtype is the 
predominant vasoconstrictor receptor activated by 5-HT in mesenteric vascular bed 
(Watts, 2002). Ketanserin, a specific 5-HT2A antagonist was used to attenuate 
vasoconstrictor responses. It is known that ketanserin has more affinity towards 5-HT2A 
and it also binds less potently to other 5-HT receptor subtypes, alpha-adrenergic and 
dopamine receptors (Nippon Yakurigaku Zasshi, 1989). At doses of ketanserin greater 
than 10nM, non-competitive blockade of vasoconstriction responses to L-tryptophan was 
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observed. This means that at higher doses, ketanserin is non-specific. At appropriate 
doses of ketanserin (2nM, 5nM and 10nM), vasoconstrictor effects of L-tryptophan were 
competitively blocked. A rightward shift in the concentration-response curve was 
observed with increasing in concentrations of ketanserin. EC50 values in the presence of 
varying concentrations of ketanserin are an indication for the rightward shift in the 
concentration-response curve to L-tryptophan. However, it is important to note that the 
Emax values in the presence of different concentrations of ketanserin were not statistically 
significant. This proves that ketanserin (2 nM, 5 nM and 10 nM) competitively blocks the 
vasoconstrictor responses to L-tryptophan. Since there is no significant variation in the 
Emax values between D- and L-stereoisomers of tryptophan, we believe that D-tryptophan 
also has the same mechanism of action.  
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5.2 Vasodilator response to tryptophan 
The current investigation also demonstrates the vasodilator effects of tryptophan 
when the perfusion pressure was elevated with methoxamine (α1 specific agonist) in 
perfused rat mesenteric vascular bed. Both L- and D-tryptophan evoked a concentration-
dependent decrease in perfusion pressure at pharmacological doses. However, due to 
unknown reasons, the vasodilator effect of L-tryptophan (Imax: 87.49 ± 1.21 %) (n=16) 
was lower than that of D-tryptophan (Imax: 95.74 ± 1.54 %) (n=4). The IC50 value for D-
tryptophan was also found to be lower than L-tryptophan.  
 
5.2.1 Role of 5-HT receptors  
As 5-HT2 receptors are involved in the vasoconstrictor effect of L-tryptophan, we 
thought of the former may also play an important role in mediating the vasodilator 
responses. So ketanserin (5 nM) was used to block 5-HT2A receptors. Ketanserin (10nM) 
was not ideal because it significantly decreased perfusion pressure which was elevated by 
methoxamine (α1-receptors). Ketanserin (2nM) did not have much effect on the elevated 
perfusion pressure but the extent of 5-HT2A receptor blockade with that dose was unclear. 
Ketanserin (5nM) was chosen, since it did not decrease elevated perfusion pressure 
significantly (<10 mmHg). Results show that vasodilator effects of L-tryptophan (at 
lower doses) were actually potentiated as compared to control. The most probable 
explanation for this result is the fact that 5-HT2A receptors are involved mostly in 
vasoconstriction responses in mesenteric vascular bed. Since vasoconstriction effect of 
this receptor is blocked by ketanserin, we actually see more vasodilatation response to L-
tryptophan. Although the Imax values in presence and absence of ketanserin did not change 
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significantly, vasodilator effect of L-tryptophan at lower doses were significantly 
potentiated in the presence of ketanserin. 
 
The possibility that other 5-HT receptors might be responsible for vasodilator 
responses to tryptophan cannot be ruled out. Literature studies reveal that 5-HT2B, 5-
HT1B/1D and 5-HT7 are involved in the vasodilator responses to 5-HT in different vascular 
preparations (Ellis et al., 1995; Centurión D et al., 2004; Terrón JA et al., 2007). 
Concentration-response curves to L-tryptophan and 5-HT were taken in presence of 
methoxamine induced constriction. The results clearly show that 5-HT evoked a 
concentration-dependent increase in perfusion pressure while the effect of L-tryptophan 
was exactly the opposite.  
 
The following conclusions can be derived from these results: 
A) L-tryptophan does not exert vasodilator effects by converting into 5-HT. If L-
tryptophan would have been converted to 5-HT and then exerted its effect, then 
vasoconstrictor effect of L-tryptophan would have been observed which is not the case. 
Thus the vasodilator effect of tryptophan is independent of its conversion to 5-HT. 
 
B) 5-HT receptors are not involved in the vasodilator response to tryptophan. We know 
that 5-HT itself is an agonist and will obviously have more affinity and intrinsic activity 
than L-tryptophan for 5-HT receptors. If any of the 5-HT receptors had been involved in 
evoking vasodilatation to L-tryptophan, then 5-HT would have evoked vasodilatation by 
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activating that receptor, which is not the case. Thus, 5-HT receptors are not responsible 
for the vasodilator effect of tryptophan. 
 
5.2.2 Role of calcium channels 
The possibility that L-tryptophan acts as a calcium channel antagonist cannot be 
ignored. Potassium chloride (KCl 100 mM) was used to constrict perfused mesenteric 
bed instead of methoxamine. KCl evoked constriction is mediated through opening of 
calcium channels. L-tryptophan responses were determined in presence of KCl induced 
constriction in mesenteric vascular bed. From the results, it is clear that L-tryptophan 
evoked a concentration-dependent vasoconstriction in perfused mesenteric bed. Thus, this 
suggests that L-tryptophan is not a calcium channel antagonist. 
 
5.2.3 Role of endothelium 
Relaxing factors released from the endothelium might play a role in mediating the 
vasodilator responses to L-tryptophan was considered. ACh was used as a test drug to 
ascertain the presence of endothelium. Endothelium denudation/removal was 
characterized by attenuation of vasodilator responses to ACh. Most of the vasodilator 
factors released from endothelium were blocked by using a combination of L-NAME, 
indomethacin (a non-selective COX inhibitor), BaCl2 (Kir inhibitor) and ouabain (Na+-K+ 
ATPase pump blocker). Responses to L-tryptophan were taken in presence and absence 
of these blockers. Results showed that there is no significant difference between 
responses in the two groups. This proves that endothelium is not involved in the 
vasodilator responses to L-tryptophan. 
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To eliminate the possibility of other vasodilatation factors released from 
endothelium, the latter was denuded with the help of sodium deoxycholate and air. 
Results indicate that there is no significant change in the Imax following endothelium 
removal. Thus for the second time, we confirm that endothelium does not play any role in 
vasodilatation response to L-tryptophan. 
 
5.2.4 Role of potassium channels    
The possibility that potassium channels located on VSMC could be targeted by L-
tryptophan to promote vasodilatation was considered. In one of the experiments, 
glibenclamide was used to block ATP-dependent potassium channels. Another set of 
experiments, we included tetraethylammonium (TEA) which is a non-selective potassium 
channel blocker. Experiments were also performed in the presence of BaCl2, which is an 
inward-rectifying potassium channel blocker (Kir blocker). Experiments aimed at 
blocking Na+-K+ ATPase pump were also carried out in the presence of ouabain. 
 
Results showed that inclusion of glibenclamide, TEA, BaCl2, L-NAME and 
ouabain did not produce any appreciable blockade of vasodilator response to L-
tryptophan. However, a significant potentiation of vasodilatation at low doses of L-
tryptophan was observed in presence of all the blockers mentioned previously. The 
reason for potentiation is currently unknown.    
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CHAPTER 6. CONCLUSION 
 
6.1 Summary of major findings for vasoconstriction responses to 
tryptophan 
 Addition of tryptophan evoked a concentration-dependent vasoconstriction in 
perfused rat mesenteric vascular bed. 
  There were no significant differences between the maximum vasoconstriction effects 
(Emax) evoked by L- and D-tryptophan. 
 EC50 values for D- and L-tryptophan were 0.25 ± 0.12* and 0.79 ± 0.30 μmol 
respectively (*p < 0.05). 
  Vasoconstrictor effects to L-tryptophan were competitively blocked by ketanserin, a 
5-HT2A selective antagonist, since there was a concentration-dependent rightward 
shift for L-tryptophan in the presence of increasing concentration of ketanserin. 
 There was no significant difference in Emax values, which proves that ketanserin at  
doses (5 nM & 10 nM) competitively blocks vasoconstrictor effects of L-tryptophan. 
  Thus tryptophan produces 5-HT dependent vasoconstrictor responses in perfused 
mesenteric vascular bed. 
 Since there was no significant change in the Emax of both L- and D-tryptophan, we 
believe it is highly likely that ketanserin blocks D-tryptophan in the same way. 
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6.2 Summary of major findings for vasodilator responses to tryptophan 
 Tryptophan produced a dose- dependent vasodilatation in methoxamine (α1- specific 
agonist) constricted perfused mesenteric vascular bed. 
 Inclusion of optimal concentration of ketanserin, a 5-HT2A selective antagonist, failed 
to affect the vasodilator responses to L-tryptophan as there were no significant 
changes in IC50 and Imax values of L-tryptophan. These data confirm that the 
vasodilator responses to L-tryptophan is not mediated by its conversion to 5-HT. 
 Contrary to vasodilator responses to L-tryptophan, addition of 5-HT produced a dose-
dependent increase in perfusion pressure when perfused mesenteric vascular bed was 
constricted with methoxamine. 
 Thus vasodilator effect of L-tryptophan is independent of its conversion to 5-HT. 
 When KCl (opens Ca2+ channels) was used to constrict perfused mesenteric vascular 
bed, L-tryptophan produced a dose-dependent increase in perfusion pressure. Thus, 
the vasodilator response to L-tryptophan is not due to blockade a Ca2+ channels. 
 TEA (tetraethylammonium), which is a non-selective Ca2+ activated potassium 
channel blocker (KCa) failed to affect the vasodilator responses to L-tryptophan. 
 Ouabain, a Na+-K+ ATPase inhibitor failed to affect the vasodilator responses to L-
tryptophan. 
 BaCl2, which is a Kir (inward rectifying potassium channel blocker) also failed to 
affect the vasodilator affect of L-tryptophan.  
 Glibenclamide (KATP channel blocker) did not have any effect on vasodilator response 
to L-tryptophan. 
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 L-NAME, indomethacin, BaCl2 and ouabain in combination failed to affect the 
vasodilator responses to L-tryptophan, an observation similar to that seen in the 
absence of endothelium. 
 Despite the above mentioned innovating and interesting findings, the likely 
mechanism that mediates vasodilator responses to L- and D-tryptophan remains to be 
established. 
 The data from the present study has ruled out the potential role of endothelium-
dependent vasodilator mechanisms. 
 In addition, the likely participation of either blockade of Ca2+ channels and activation 
of different vascular K+ channels has been ruled out. It is therefore likely that L-
tryptophan could affect events at the level of Ca2+-independent mechanisms such as 
Rho-Kinase that regulates VSM tone to promote endothelium-independent 
vasodilatation.     
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6.3 Significance of tryptophan study 
Tryptophan is one of the essential amino acids. It has been known for years that 
high protein diet increases the plasma concentration of amino acids. To our 
understanding, literature does not reveal any in-vitro study to explain the vascular effects 
of tryptophan. In-vivo studies using tryptophan were carried out in 1980s. 
Antihypertensive action of L-tryptophan (in-vivo) in spontaneously hypertensive rats 
(SHR) rats observed earlier were attributed to activation of serotonergic mechanism 
(Sved et al., 1982). In 1983, Wolf et al., proved that antihypertensive action of L-
tryptophan is not mediated through brain serotonin or serotonergic neurons. Again in 
1984, Wolf et al., proved that the antihypertensive effects of L-tryptophan in 
normotensive and SHR rats cannot be entirely explained through changes in brain 
serotonin levels. Antihypertensive action of indolepyruvic acid- a keto analogue of 
tryptophan was believed to be correlated with cerebral serotonin metabolism (Squadrito 
et al., 1989). Studies on chronic dietary treatment of L-tryptophan on SHR reduced the 
mean blood pressure but the exact mechanism of action was not established (Fregly et al., 
1988). 
 
To our knowledge, this is the first report showing the anti-hypertensive effect of 
L-tryptophan in an ex-vivo model of perfused mesenteric vascular bed. The data from the 
present study suggests that the significant vasodilatation seen in the perfused mesenteric 
vascular bed could contribute to the possible antihypertensive action reported earlier. We 
also believe that vasodilatation of 85-90% in resistance vessels of perfused mesenteric 
vascular bed might be the reason of fall in blood pressure as seen with SHR in previous 
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studies. (Wolf et al.,1984; Sved et al.,1982). We also confirm the presence of 
serotonergic system in the blood vessels as suggested earlier (Linder et al., 2007). 
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6.4 Limitations of the present study 
1) The present study concludes that the vasoconstrictor responses to both L- and D-
tryptophan were mediated by their likely conversion to serotonin (5-HT). This was based 
on the dose-dependent competitive shift characteristics that both isomers show in the 
presence of ketanserin. At this time, it is not known whether the level of shift attained in 
the dose-response curves to 5-HT in the presence of the same concentrations of 
ketanserin were similar or higher. Moreover, further studies of determination of the  
comparison of pA2 values for ketanserin against L- and D-tryptophan vs 5-HT-evoked 
vasoconstrictor responses would settle whether all of the vasoconstrictor responses to 
both D- and L-tryptophan are indeed mediated by their conversion to 5-HT.  
 
2) In methoxamine constricted but not KCl depolarized tissues, both L- and D-tryptophan 
evoked vasodilatation and this is not mediated by 5-HT since addition of 5-HT enhanced 
the vasoconstrictor responses further in both methoxamine constricted and KCl 
depolarized states. The mechanism that contributes to the vasodilator effect has not been 
elucidated in the present study although the likely role for endothelial vasodilator 
mediators, as well as vascular KATP and BKCa channel as well as voltage operated Ca2+ 
channel have been ruled out as possible candidates. Further studies are warranted to 
resolve the mechanism underlying endothelium-independent direct vasodilator responses 
to L-tryptophan. 
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6.5 Future directions 
1) While the data from the present study provides evidence that both L-tryptophan and D-
tryptophan exert a biphasic effect [vasoconstrictor and vasodilator responses] in the 
perfused mesenteric vascular bed, it is unclear whether this phenomenon exists in other 
vascular beds.  Instead of repeating or extending the study to other vascular beds and 
using isolated blood vessels, it would be appropriate to establish first the regional 
hemodynamic effects of L- and D-tryptophan using microsphere distribution 
methodology.  This will give us an estimate of the vascular beds that are sensitive to the 
actions of these amino acids in an in vivo model. This will also give an estimate of the 
changes in total peripheral resistance, cardiac output evoked by D- and L-tryptophan.  
Based on the above, more detailed mechanistic studies could be performed using isolated 
blood vessels/ perfused vascular bed preparations that are sensitive to tryptophan. 
  
2) Previous studies have shown L-tryptophan reduces blood pressure in SHR (Wolf et al., 
1984; 1984; Sved et al.,1982; Squadrito et al., 1989; Fregly et al., 1988). However, these 
studies were performed using either the tail cuff methodology or direct catheter recording 
of BP in anaesthetized rats. Both methods have serious limitations.  It is now feasible to 
examine the chronic / long term effects of infusion of L- and D- tryptophan in conscious, 
freely moving rats using radiotelemetry methodology.  Such studies, a logical extension 
will enhance the significance of this study. 
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APPENDIX 
The following few pages indicate that permission has been taken from the author/journal 
to incorporate the exact figures in this thesis. 
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